| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
| Targets |
Sucrose Octasulfate Potassium Salt does not have a single defined molecular target but acts through its physical and chemical properties. As a component of sucralfate, it forms a viscous, adhesive barrier that binds to ulcerated mucosal surfaces, protecting them from acid, pepsin, and bile salts. The compound inhibits peptic hydrolysis and raises gastric pH. Its highly sulfated nature contributes to its mucosal protective properties.
|
|---|---|
| ln Vitro |
In vitro, Sucrose Octasulfate Potassium Salt has been shown to protect esophageal epithelium against acid injury. The compound inhibits peptic hydrolysis and raises gastric pH. It forms a viscous, adhesive barrier that binds to ulcerated mucosal surfaces. These in vitro studies demonstrate the compound's potential for protecting the gastrointestinal mucosa.
|
| ln Vivo |
In vivo, Sucrose Octasulfate Potassium Salt is used as a component of the gastrointestinal protectant sucralfate. Sucralfate is used for the treatment of duodenal ulcers, gastric ulcers, and other gastrointestinal conditions. The compound protects the gastrointestinal mucosa by forming a barrier and inhibiting peptic hydrolysis.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable for Sucrose Octasulfate Potassium Salt as it is not a drug that targets specific enzymes or receptors. However, assays for mucoadhesion and barrier formation are performed. These include measuring the compound's ability to bind to mucosal surfaces and form protective barriers. The compound's effects on gastric pH and pepsin activity are also measured.
|
| Cell Assay |
In vitro cellular studies with Sucrose Octasulfate Potassium Salt are limited. The compound is primarily studied for its physical and chemical properties rather than direct cellular effects. However, studies on mucosal protection may use epithelial cell cultures to assess barrier function and protection against acid injury.
|
| Animal Protocol |
In vivo animal experiments are performed using models of gastric and duodenal ulcers. Animals are administered Sucrose Octasulfate Potassium Salt or sucralfate formulations orally. Ulcer healing, mucosal protection, and gastric pH are assessed. These studies evaluate the compound's efficacy in protecting the gastrointestinal mucosa.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Sucrose Octasulfate Potassium Salt include its high water solubility (≥100 mg/mL) and hygroscopic nature. The compound has a molecular formula C12H14K8O35S8. It melts at >230°C. Storage under dry conditions is important due to its hygroscopicity. The compound should be protected from moisture. Purity is typically ≥95%.
|
| Toxicity/Toxicokinetics |
Sucrose Octasulfate Potassium Salt is also known as Potassium sucrose octasulfate and KSOS. It is a component of the gastrointestinal protectant sucralfate. The compound inhibits peptic hydrolysis and raises gastric pH, protecting esophageal epithelium against acid injury. It is a highly sulfated, water-soluble oligosaccharide salt and is used as a reference standard and in research on gastrointestinal protection. The compound has the molecular formula C12H14K8O35S8.
|
| Additional Infomation |
See also: Sucrosofate (has active moiety).
|
| Molecular Formula |
C12H14O35S8-8.8[K+]
|
|---|---|
| Molecular Weight |
1287.52496
|
| Exact Mass |
1285.417
|
| CAS # |
73264-44-5
|
| PubChem CID |
23725031
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
>230ºC
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
42
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
70
|
| Complexity |
2130
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C(C1C(C(C(C(O1)OC2(COS(=O)(=O)[O-])C(C(C(COS(=O)(=O)[O-])O2)OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+]
|
| InChi Key |
XISWAUUBQBEDFB-QRDGSJRXSA-F
|
| InChi Code |
InChI=1S/C12H22O35S8.8K/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18;;;;;;;;/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36);;;;;;;;/q;8*+1/p-8/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;/m1......../s1
|
| Chemical Name |
octapotassium;[(2R,3R,4S,5R,6R)-2-[(2S,3S,4R,5R)-3,4-disulfonatooxy-2,5-bis(sulfonatooxymethyl)oxolan-2-yl]oxy-3,5-disulfonatooxy-6-(sulfonatooxymethyl)oxan-4-yl] sulfate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7767 mL | 3.8834 mL | 7.7668 mL | |
| 5 mM | 0.1553 mL | 0.7767 mL | 1.5534 mL | |
| 10 mM | 0.0777 mL | 0.3883 mL | 0.7767 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
